

Prevalence of Vitamin-D Deficiency among Individuals Diagnosed with Alopecia Areata

Sumyra Saleem¹, Muhammad Erfan², Muhammad Faisal Bacha³, Ikra Khan⁴, Areeba Jabbar⁵ and Seemal Akram⁶

ABSTRACT

Objective: An immunological response causes hair follicle inflammation in alopecia areata (AA). Alopecia totalis, universalis, and patchy hair loss may occur. This Study examined vita min-d deficiency in alopecia areata patients.

Study Design: A case-control study

Place and Duration of Study: This study was conducted at the Department of Dermatology, Farooq Hospital Islamabad from October 2022 to July 2023.

Methods: This case-control Study was done on 45 alopecia areata (AA) patients and 45 controls. Serum 25-hydroxy vita min-d [25-(OH)-D3] levels were measured in all individuals. The SALT was used to assess alopecia's severity. Venous blood samples were taken in the lab for 25-(OH) vita min-d enzyme immunoassay on a chemical analyzer. The analytical data was recorded in SPSS 27.

Results: The mean age of study and control group was 22.94 ± 7.92 years and 23.84 ± 8.46 years respectively. The median (IQR) of vita min-d level of study and control group was 14.6 ± 17.9 ng/dL and 23.2 ± 15.32 ng/dL respectively. The incidence of Unifocal, Multifocal, Ophiasis, Alopecia universalis, and Alopecia totalis were different pattern of alopecia found in 20% (n=9), 51.1% (n=23), 11.1% (n=5), 6.7% (n=3), and 11.1% (n=5) respectively. Significant differences between study and control group were seen in terms of vita min-d levels based on SALT score that was 23.5 ng/dl in S1 compared to 7.9 ng/dl in S5.

Conclusion: It has been observed that a significant association between lower serum vita min-d levels and alopecia areata (AA) compared to the levels in healthy controls. This suggests that there may be a correlation between AA and vita min-d deficiency, as the mean vita min-d levels in patients were notably lower than healthy control group.

Key Words: Alopecia areata, vita min-d, autoimmune disease, hair loss

Citation of article: Saleem S, Erfan M, Bacha MF, Khan I, Jabbar A, Akram S. Prevalence of Vitamin-D Deficiency among Individuals Diagnosed with Alopecia Areata. Med Forum 2023;34(12):66-69. doi:10.60110/medforum.341216.

INTRODUCTION

¹. Department of Dermatology, Federal Government Polyclinic (PGMI), Islamabad.

². Department of Dermatology, Akhtar Saeed Medical College / Farooq Hospital Islamabad.

³. Department of Medicine, Akhtar Saeed Medical College, Rawalpindi.

⁴. Department of Dermatology, Pak Emirates Military Hospital, Rawalpindi.

⁵. Department of Dermatology, Neuface Medical Centre, Islamabad.

⁶. Department of Dermatology, Nusrat Hospital, Peshawar Road, Rawalpindi.

Correspondence: Muhammad Erfan, Assistant Professor, Department of Dermatology, Akhtar Saeed Medical College / Farooq Hospital Islamabad.

Contact No: 0334-0541816

Email: Erfan_khattak@yahoo.com

Received: August, 2023

Accepted: October, 2023

Printed: December, 2023

An autoimmune condition known as alopecia areata (AA) that affects only certain organs is characterized by T-cell infiltration and cytokine release around anagen stage hair follicles.^[1] This condition has long been recognized for its associations with HLA Class I and II, as well as its occurrence alongside various autoimmune disorders including rheumatoid arthritis (RA), type I diabetes mellitus (DM), vitiligo, systemic lupus erythematosus (SLE), thyroiditis, pemphigus vulgaris (PV), pernicious anemia, and celiac disease^[2, 3]. A kind of hair loss called alopecia areata (AA) does not leave scars behind. It may show up in a variety of ways, from isolated areas of hair loss to alopecia totalis (total baldness) and alopecia universalis (hair loss across the body)^[4]. Individuals have a 1.7% lifetime chance of developing alopecia areata (AA), with a recorded prevalence estimated to be between 0.1% and 0.2%. References^[5,6]. With alopecia areata (AA), the incidence of autoimmune disorders rose by 16%^[7]. Numerous studies on vita min-d have shown how important it is for immune system regulation^[8]. The maintenance of calcium homeostasis and bone health may be strongly influenced by the secosteroid hormone known as vita min-d. Although 1,

25-dihydroxyvita min-d (1, 25(OH)2D3) is the physiologically active form, its short half-life (less than 4 hours) may sometimes result in normal levels, even in cases of vita min-d insufficiency. Consequently, this marker is seen to be a more trustworthy indication as it captures vita min-d exposure from all sources and offers a consistent picture of vita min-d levels.^[9, 10] Furthermore, calcium and vitamin D both have immunomodulatory properties. A lack of vitamin D has been connected to a variety of autoimmune conditions, such as vitiligo, psoriasis, and systemic lupus erythematosus.^[11,12] The correlation between vita min-d deficiency and alopecia areata (AA) is still a subject of debate, and conflicting data on this association exist. Therefore, the objective of the current study was to determine the prevalence of vita min-d Deficiency among Individuals Diagnosed with Alopecia Areata.

METHODS

45 alopecia areata (AA) patients and 45 controls. All patients had vita min-d levels checked and SALT was used to assess disease severity. Venous blood samples were taken in the lab for twenty five-(OH) Enzyme immunoassay for vitamin D on a chemical analyzer. Following signed notification consent, demographic, illness, family, and atopy histories were gathered. Several hair loss patterns were recorded: totalis, unifocal, universalis, ophiasis, and multifocal. SALT reported illness severity as S1–S5. The hospital laboratory analyzed vita min-d levels in 5 ml blood samples from each patient. vita min-deficiency, insufficiency, and sufficiency were classified as <20, 21-29, and 30 ng/dl. The data obtained from the analysis was recorded using SPSS version 27. The mean ± standard deviation (SD) was calculated for continuous variables such as age and the number of patches. Qualitative parameters such as SALT score, family history of the disease, disease’s duration, history of atopy, and alopecia pattern were presented as frequencies and percentages.

RESULTS

The overall mean age of study and control group was 22.94 ±7.92 years and 23.84 ±8.46 years respectively. The median (IQR) of vita min-d level of study and control group was 14.6±17.9 ng/dL and 23.2±15.32 ng/dL respectively. The incidence of Unifocal, Multifocal, Oophiasis, Alopecia universalis, and Alopecia totalis were different pattern of alopecia found in 20% (n=9), 51.1% (n=23), 11.1% (n=5), 6.7% (n=3), and 11.1% (n=5) respectively. Significant differences between study and control group were seen in terms of vita min-d levels based on SALT score that was 23.5 ng/dl in S1 compared to 7.9 ng/dl in S5. Each group comprised 18 individuals (40%) who were male and 27 individuals (60%) who were female. Nail pitting was

observed in 16 (35.6%) of the patients, while none were observed in the control group. Demographic details of patients are shown in Table-I. Distribution of patients based on their disease duration are shown in Figure-1. Figure-2 illustrate the Pattern of alopecia. SALT score are shown in Table-II.

Table No. 1: Demographic and baseline characteristics of patients

Parameters	Study group (N=45)	Control (N=45)
Age (years)	22.94 ±7.92	23.84 ±8.46
vita min-d level (ng/dL)	14.6±17.9	23.2 ±15.32
Gender N (%)		
Male	27 (60%)	27 (60%)
Female	18 (40%)	18 (40%)
Family history of Disease	13 (28.9%)	4 (8.9%)
Family history of atopy	10 (22.2%)	7 (15.6%)




Figure No. 1: Distribution of patients based on their disease duration (N=45).




Figure No. 2: Pattern of alopecia (N=45)

Table No. 2: SALT score

SALT Score	N (%) [(ng/dl)]
S1	7 (15.6%) [23.5]
S2	10 (22.2%) [22.5]
S3	18 (40%) [18.6]
S4	3 (6.7%) [12.4]
S5	7 (15.6%) [7.9]

DISCUSSION

Alopecia areata predominantly affects individuals at a young age and is more prevalent in females. The most prominent alopecia areata pattern was multifocal alopecia, characterized by the presence of two or more patches. A majority of patients sought medical attention within one year of experiencing symptoms. Moreover, in the study, twelve patients (27%) had a positive family history of the disease, in contrast to only two individuals in the healthy control group. Additionally, a higher number of alopecia areata patients were found to have a family history of atopy compared to the healthy controls. The present study's findings show that those with "alopecia areata" (AA) had significantly lower average vita min-d levels than did healthy controls, with a p-value of less than 0.05 indicating statistical significance. Surprisingly, a more severe vita min-d deficiency was linked to more severe instances of AA^[13,14]. Yilmaz et al.^[15] reported that AA patients had lower vita min-d serum levels than control cases. The study found that 85% of their cohort had 25(OH)D deficiency, a slightly lower prevalence than the observed value in the present study. Their study reported no significant correlation between AA severity and vita min-d levels. On contrary, vita min-d levels were inversely related to AA severity as observed in the present study. These variations underscore the complexity of the association of vita min-d levels with AA severity, suggesting that additional factors may contribute to these associations.

vita min-d, generated through the skin conversion process of pro to pre-vitamin, plays a role in enhancing tyrosinase activity and melanin synthesis. Consequently, it contributes to pigmentation and exhibits diverse immunoregulatory functions^[16-20]. vita min-d analogues are recognized for their ability to promote repigmentation in individuals with vitiligo patches^[21, 22].

The potential pathogenesis of "alopecia areata" (AA) is likely associated with autoimmunity and inflammation. An earlier report revealed that immunomodulatory effects of vita min-d exerts by pro-inflammatory cytokines inhibition^[23]. The pro-inflammatory cytokines upregulation comes from vita min-d deficiency in AA. Consequently, this could lead to increased systemic inflammation in AA, which is recognized as an autoimmune disease affecting the hair follicles^[24].

Another study reported the "alopecia areata" (AA) relapse as a seasonal variation, which indicated the lower vita min-d levels in winter season^[25]. In the study groups of both patients and controls in this study, vita min-d levels were lower, suggesting a potential vita min-d deficiency in the general population^[26].

CONCLUSION

A significant association between lower serum vita min-d levels and "alopecia areata" (AA) compared to the levels observed in healthy controls. This suggests that there may be a correlation between AA and vita min-d deficiency, as the mean vita min-d levels in patients were notably lower than healthy control group.

Author's Contribution:

Concept & Design of Study: Sumyra Saleem
 Drafting: Muhammad Erfan,
 Muhammad Faisal Bacha
 Ikra Khan, Areeba
 Data Analysis: Jabbar, Seemal Akram
 Revisiting Critically: Sumyra Saleem,
 Muhammad Erfan
 Final Approval of version: Sumyra Saleem

Conflict of Interest: The study has no conflict of interest to declare by any author.

Source of Funding: None

Ethical Approval: No.FH/ERB/REF/220/2022 dated 08.05.2022

REFERENCES

1. Tsai TY, Huang YC. vita min-d deficiency in patients with "alopecia areata": A systematic review and meta-analysis. *J Am Acad Dermatol* 2018;78(1):207-209.
2. Lee S, Kim B, Lee C, et al. Increased prevalence of vita min-d deficiency in patients with "alopecia areata": a systematic review and meta-analysis. *J Eur Acad Dermatol Venereol* 2018;32(7):1214-1221.
3. Daroach M, Narang T, Saikia UN, Sachdeva N, Sendhil Kumaran M. Correlation of vita min-d and vita min-d receptor expression in patients with "alopecia areata": a clinical paradigm. *Int J Dermatol* 2018;57:217-22.
4. Bhat YJ, Latif I, Malik R, Hassan I, Sheikh G, Lone KS, et al. vita min-d level in "alopecia areata". *Ind J Dermatol* 2017;62:407-10.
5. Ghafoor R, Anwar MI. vita mind deficiency in "alopecia areata". *J Coll Physicians Surg Pak* 2017;27:200-2.
6. Erpolat S, Sarifakioglu E, Ayyildiz A. 25-hydroxyvita min-d status in patients with "alopecia areata". *Postepy Dermatol Alergol* 2017;34: 248-52.
7. Singh K, Sharma S, Singh UR, Bhattacharya SN. A comparison of vertical and transverse sections in the histological diagnosis of "alopecia areata" scalp biopsy specimens. *Int J Trichol* 2016;8(3):111-5.
8. Pedullà M, Fierro V, Marzuillo P, Capuano F, Miraglia del Giudice E, Ruocco E. Skin disease

- and thyroid autoimmunity in atopic South Italian children. *World J Clin Pediatr* 2016;5(3):288–92.
9. Bakry OA, El-Faragy SM, El-Shafiee MK, Soliman A. Serum vita min-d in patients with “alopecia areata”. *Ind Dermatol Online J* 2016;7:371-7.
 10. Zhu B, Zhang L, Wang J, Tan G. vita min-d supplementation for patients with “alopecia areata”: A protocol for systematic review and meta-analysis. *Med* 2022;101(42):e31089.
 11. Strazzulla LC, Wang EHC, Avila L, et al. “alopecia areata”: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. *J Am Acad Dermatol* 2018;78:1–12.
 12. Darwin E, Hirt PA, Fertig R, et al. “alopecia areata”: review of epidemiology, clinical features, pathogenesis, and new treatment options. *Int J Trichology*. 2018;10:51–60.
 13. Trüeb RM, Dias MFRG. “alopecia areata”: a comprehensive review of pathogenesis and management. *Clin Rev Allergy Immunol* 2018;54:68–87.
 14. Liu Y, Li J, Liang G, et al. Association of “alopecia areata” with vita min-d and calcium levels: a systematic review and meta-analysis. *Dermatol Ther (Heidelb)* 2020;10:967–83.
 15. Yilmaz N, Serarslan G, Gokce C. vita min-d concentrations are decreased in patients with “alopecia areata”. *Vitam Trace Elem* 2012;1:105-9.
 16. Daroach M, Narang T, Saikia UN, et al. Correlation of vita min-d and vita min-d receptor expression in patients with “alopecia areata”: a clinical paradigm. *Int J Dermatol* 2018;57:217–22.
 17. Unal M, Gonulalan G. Serum vita min-d level is related to disease severity in pediatric “alopecia areata”. *J Cosmet Dermatol*. 2018;17:101–4.
 18. Navarro-Triviño FJ, Arias-Santiago S, et al. vita min-d and the skin: a review for dermatologists. *Vitamina D y la piel. Una revisión para dermatólogos. Actas Dermosifiliogr* 2019;110:262–72.
 19. Olsen EA, Roberts J, Sperling L, et al. Objective outcome measures: collecting meaningful data on “alopecia areata”. *J Am Acad Dermatol* 2018;79:470–478.e3.
 20. Jang YH, Moon SY, Lee WJ, et al. “alopecia areata” progression index, a scoring system for evaluating overall hair loss activity in “alopecia areata” patients with pigmented hair: a development and reliability assessment. *Dermatol* 2016;232:143–9.
 21. Tran PT, Chen A, Yi L, Goh C. vita min-d levels in “alopecia areata” and other alopecias: A retrospective case–control study at a single institution. *Int J Trichol* 2022;14(5):175.
 22. Darwin E, Hirt PA, Fertig R, Doliner B, Delcanto G, Jimenez JJ. Alopecia areata: Review of epidemiology, clinical features, pathogenesis and new treatment options. *Int J Trichol* 2018;10(2):51-60.
 23. Strazzulla LC, Wang HCE, Avila L, Sicco LK, Brinster N, Christiano AM, et al. Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. *J Am Acad Dermatol* 2018; 78(1):1-12.
 24. Simakou T, Butcher JP, Reid S, Henriquez FL. “alopecia areata”: A multifactorial autoimmune condition. *J Autoimmun* 2019;98(1):74-85.
 25. Lin X, Meng X, Song Z. VitaminD and “alopecia areata”: possible roles in pathogenesis and potential implications for therapy. *Am J Transl Res* 2019; 11(9): 5285-5300.
 26. Rehman F, Dogra N, Wani MA. Serum Vitamin D levels and Alopecia areata-A hospital-based case-control study from North-India. *Int J Trichol* 2019;11(2):49-57.